A phase II GETNE-DUTHY trial is evaluating durvalumab plus tremelimumab in advanced thyroid cancer, according to the new report describing the study led by Capdevila, Hernando, and Molina-Cerillo. The work tests whether the dual checkpoint approach can improve disease control in a setting where options remain limited. The trial details focus on how the immunotherapy combination performs in this specific tumor type and the risks seen with regimen exposure. For clinicians and developers, thyroid cancer is a niche but persistent target for checkpoint innovation, particularly as investigators look for biomarker-driven strategies. GETNE-DUTHY’s results add to the growing set of studies exploring multi-agent immunotherapy in endocrinology-associated oncology indications.